| Study . | Comparisons . | Sample size . | Age (mean) . | BMI (mean) . | Treatment-naïve(%) . | Outcomes . |
|---|---|---|---|---|---|---|
| (Amer et al., 2017) | Letrozole vs CC | 159 | 28.2 ± 4.3 | 27.5 ± 4.8 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Bayar et al., 2006) | Letrozole vs CC | 80 (74) | 31.4 ± 4.0 | NA | 100% | Clinical pregnancy, multiple pregnancy, time to pregnancy |
| (Homburg et al., 2012) | FSH vs CC | 302 | 29.5 ± 3.9 | 25.4 ± 5.6 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)A | Metformin vs placebo | 65 | 29.6 ± 4.2 | 37.8 ± 3.5 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)B | CC + metformin vs CC vs metformin | 106 | 28.7 ± 4.4 | 26.5 ± 3.7 | 78% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Kar 2012) | Letrozole vs CC | 103 | NA | 25.9 ± 3.4 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Kar and Sanchita 2015) | CC + metformin vs CC vs metformin | 105 (81) | 25.6 ± 3.3 | 26.1 ± 4.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Leanza et al., 2014) | CC + metformin vs CC | 56 | 31.1 ± 2.0 | 29.5 ± 1.4 | 100% | Clinical pregnancy, miscarriage, ovulation |
| (Legro et al., 2007) | CC + metformin vs CC vs metformin | 626 | 28.1 ± 4.0 | 35.2 ± 8.7 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Legro et al., 2014) | Letrozole vs CC | 750 | 28.9 ± 4.3 | 35.1 ± 9.3 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Liu et al., 2017) | CC + metformin vs letrozole vs CC | 203 | 27.0 ± 3.0 | 21.5 ± 2.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Lord et al., 2006) | Metformin vs placebo | 44 | 29.1 ± 4.9 | 34.8 ± 7.0 | unknown | Clinical pregnancy, ovulation |
| (Moll et al., 2006) | CC + metformin vs CC | 225 | 28.4 ± 3.8 | 28.1 ± 6.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Morin-Papunen et al., 2012) | Metformin vs placebo | 320 | 28.2 ± 4.0 | 27.2 ± 6.3 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Nazik and Kumtepe, 2012) | Letrozole vs CC | 64 | 26.8 ± 5.6 | 25.1 ± 4.3 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Palomba et al., 2005) | CC vs metformin | 100 | 26.2 ± 4.4 | 26.7 ± 2.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Sahin et al., 2004) | CC + metformin vs CC | 21 | 25.1 ± 3.3 | 28.2 ± 3.7 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Vegetti et al., 1999) | Tamoxifen vs CC | 95 (108) | 30.9 ± 3.1 | 22.7 ± 4.2 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Williams et al., 2009) | CC + metformin vs CC | 59 (55) | NA | NA | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Wu et al., 2017) | CC vs placebo | 500 | 27.9 ± 3.3 | 24.5 ± 4.2 | 70% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| Study . | Comparisons . | Sample size . | Age (mean) . | BMI (mean) . | Treatment-naïve(%) . | Outcomes . |
|---|---|---|---|---|---|---|
| (Amer et al., 2017) | Letrozole vs CC | 159 | 28.2 ± 4.3 | 27.5 ± 4.8 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Bayar et al., 2006) | Letrozole vs CC | 80 (74) | 31.4 ± 4.0 | NA | 100% | Clinical pregnancy, multiple pregnancy, time to pregnancy |
| (Homburg et al., 2012) | FSH vs CC | 302 | 29.5 ± 3.9 | 25.4 ± 5.6 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)A | Metformin vs placebo | 65 | 29.6 ± 4.2 | 37.8 ± 3.5 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)B | CC + metformin vs CC vs metformin | 106 | 28.7 ± 4.4 | 26.5 ± 3.7 | 78% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Kar 2012) | Letrozole vs CC | 103 | NA | 25.9 ± 3.4 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Kar and Sanchita 2015) | CC + metformin vs CC vs metformin | 105 (81) | 25.6 ± 3.3 | 26.1 ± 4.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Leanza et al., 2014) | CC + metformin vs CC | 56 | 31.1 ± 2.0 | 29.5 ± 1.4 | 100% | Clinical pregnancy, miscarriage, ovulation |
| (Legro et al., 2007) | CC + metformin vs CC vs metformin | 626 | 28.1 ± 4.0 | 35.2 ± 8.7 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Legro et al., 2014) | Letrozole vs CC | 750 | 28.9 ± 4.3 | 35.1 ± 9.3 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Liu et al., 2017) | CC + metformin vs letrozole vs CC | 203 | 27.0 ± 3.0 | 21.5 ± 2.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Lord et al., 2006) | Metformin vs placebo | 44 | 29.1 ± 4.9 | 34.8 ± 7.0 | unknown | Clinical pregnancy, ovulation |
| (Moll et al., 2006) | CC + metformin vs CC | 225 | 28.4 ± 3.8 | 28.1 ± 6.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Morin-Papunen et al., 2012) | Metformin vs placebo | 320 | 28.2 ± 4.0 | 27.2 ± 6.3 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Nazik and Kumtepe, 2012) | Letrozole vs CC | 64 | 26.8 ± 5.6 | 25.1 ± 4.3 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Palomba et al., 2005) | CC vs metformin | 100 | 26.2 ± 4.4 | 26.7 ± 2.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Sahin et al., 2004) | CC + metformin vs CC | 21 | 25.1 ± 3.3 | 28.2 ± 3.7 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Vegetti et al., 1999) | Tamoxifen vs CC | 95 (108) | 30.9 ± 3.1 | 22.7 ± 4.2 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Williams et al., 2009) | CC + metformin vs CC | 59 (55) | NA | NA | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Wu et al., 2017) | CC vs placebo | 500 | 27.9 ± 3.3 | 24.5 ± 4.2 | 70% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| Study . | Comparisons . | Sample size . | Age (mean) . | BMI (mean) . | Treatment-naïve(%) . | Outcomes . |
|---|---|---|---|---|---|---|
| (Amer et al., 2017) | Letrozole vs CC | 159 | 28.2 ± 4.3 | 27.5 ± 4.8 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Bayar et al., 2006) | Letrozole vs CC | 80 (74) | 31.4 ± 4.0 | NA | 100% | Clinical pregnancy, multiple pregnancy, time to pregnancy |
| (Homburg et al., 2012) | FSH vs CC | 302 | 29.5 ± 3.9 | 25.4 ± 5.6 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)A | Metformin vs placebo | 65 | 29.6 ± 4.2 | 37.8 ± 3.5 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)B | CC + metformin vs CC vs metformin | 106 | 28.7 ± 4.4 | 26.5 ± 3.7 | 78% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Kar 2012) | Letrozole vs CC | 103 | NA | 25.9 ± 3.4 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Kar and Sanchita 2015) | CC + metformin vs CC vs metformin | 105 (81) | 25.6 ± 3.3 | 26.1 ± 4.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Leanza et al., 2014) | CC + metformin vs CC | 56 | 31.1 ± 2.0 | 29.5 ± 1.4 | 100% | Clinical pregnancy, miscarriage, ovulation |
| (Legro et al., 2007) | CC + metformin vs CC vs metformin | 626 | 28.1 ± 4.0 | 35.2 ± 8.7 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Legro et al., 2014) | Letrozole vs CC | 750 | 28.9 ± 4.3 | 35.1 ± 9.3 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Liu et al., 2017) | CC + metformin vs letrozole vs CC | 203 | 27.0 ± 3.0 | 21.5 ± 2.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Lord et al., 2006) | Metformin vs placebo | 44 | 29.1 ± 4.9 | 34.8 ± 7.0 | unknown | Clinical pregnancy, ovulation |
| (Moll et al., 2006) | CC + metformin vs CC | 225 | 28.4 ± 3.8 | 28.1 ± 6.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Morin-Papunen et al., 2012) | Metformin vs placebo | 320 | 28.2 ± 4.0 | 27.2 ± 6.3 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Nazik and Kumtepe, 2012) | Letrozole vs CC | 64 | 26.8 ± 5.6 | 25.1 ± 4.3 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Palomba et al., 2005) | CC vs metformin | 100 | 26.2 ± 4.4 | 26.7 ± 2.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Sahin et al., 2004) | CC + metformin vs CC | 21 | 25.1 ± 3.3 | 28.2 ± 3.7 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Vegetti et al., 1999) | Tamoxifen vs CC | 95 (108) | 30.9 ± 3.1 | 22.7 ± 4.2 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Williams et al., 2009) | CC + metformin vs CC | 59 (55) | NA | NA | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Wu et al., 2017) | CC vs placebo | 500 | 27.9 ± 3.3 | 24.5 ± 4.2 | 70% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| Study . | Comparisons . | Sample size . | Age (mean) . | BMI (mean) . | Treatment-naïve(%) . | Outcomes . |
|---|---|---|---|---|---|---|
| (Amer et al., 2017) | Letrozole vs CC | 159 | 28.2 ± 4.3 | 27.5 ± 4.8 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Bayar et al., 2006) | Letrozole vs CC | 80 (74) | 31.4 ± 4.0 | NA | 100% | Clinical pregnancy, multiple pregnancy, time to pregnancy |
| (Homburg et al., 2012) | FSH vs CC | 302 | 29.5 ± 3.9 | 25.4 ± 5.6 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)A | Metformin vs placebo | 65 | 29.6 ± 4.2 | 37.8 ± 3.5 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Johnson et al., 2010)B | CC + metformin vs CC vs metformin | 106 | 28.7 ± 4.4 | 26.5 ± 3.7 | 78% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Kar 2012) | Letrozole vs CC | 103 | NA | 25.9 ± 3.4 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Kar and Sanchita 2015) | CC + metformin vs CC vs metformin | 105 (81) | 25.6 ± 3.3 | 26.1 ± 4.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Leanza et al., 2014) | CC + metformin vs CC | 56 | 31.1 ± 2.0 | 29.5 ± 1.4 | 100% | Clinical pregnancy, miscarriage, ovulation |
| (Legro et al., 2007) | CC + metformin vs CC vs metformin | 626 | 28.1 ± 4.0 | 35.2 ± 8.7 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Legro et al., 2014) | Letrozole vs CC | 750 | 28.9 ± 4.3 | 35.1 ± 9.3 | 45% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Liu et al., 2017) | CC + metformin vs letrozole vs CC | 203 | 27.0 ± 3.0 | 21.5 ± 2.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Lord et al., 2006) | Metformin vs placebo | 44 | 29.1 ± 4.9 | 34.8 ± 7.0 | unknown | Clinical pregnancy, ovulation |
| (Moll et al., 2006) | CC + metformin vs CC | 225 | 28.4 ± 3.8 | 28.1 ± 6.9 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Morin-Papunen et al., 2012) | Metformin vs placebo | 320 | 28.2 ± 4.0 | 27.2 ± 6.3 | 69% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Nazik and Kumtepe, 2012) | Letrozole vs CC | 64 | 26.8 ± 5.6 | 25.1 ± 4.3 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Palomba et al., 2005) | CC vs metformin | 100 | 26.2 ± 4.4 | 26.7 ± 2.3 | 100% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
| (Sahin et al., 2004) | CC + metformin vs CC | 21 | 25.1 ± 3.3 | 28.2 ± 3.7 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Vegetti et al., 1999) | Tamoxifen vs CC | 95 (108) | 30.9 ± 3.1 | 22.7 ± 4.2 | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Williams et al., 2009) | CC + metformin vs CC | 59 (55) | NA | NA | 100% | Clinical pregnancy, time to pregnancy, ovulation |
| (Wu et al., 2017) | CC vs placebo | 500 | 27.9 ± 3.3 | 24.5 ± 4.2 | 70% | Live birth, clinical pregnancy, time to pregnancy, miscarriage, multiple pregnancy, ovulation |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
